Emanuel Petricoin has been the co-director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005, where he is a university professor. Prior to this position, he served as co-director of the FDA-NCI Clinical Proteomics Program and was a senior investigator within the Center for Biologics Evaluation and Research at the FDA from 1993-2005. Petricoin received his Ph.D. in microbiology from the University of Maryland in 1990.
He is a co-founder of four life science companies, including Perthera, Inc., which offers precision therapy services for cancer patients around the U.S., and Ceres Nanosciences, Inc., which has developed and commercialized the first direct antigen urine test for Lyme disease detection. He is a co-inventor on 40 filed and published patents, and has authored over 375 peer-reviewed publications and invited reviews. He has authored over 40 book chapters, is on the editorial board of Proteomics, Biomedical Microdevices, Proteomics—Clinical Applications, Proteomics-Protocols, Molecular Carcinogenesis, Journal of Personalized Medicine, and is a senior editor for Cancer Epidemiology Biomarkers and Prevention.
Petricoin is a founding member of the Human Proteomic Organization (HUPO) and the US HUPO. He has received numerous awards, including the University Professorship at George Mason University, the NIH Director’s Award, and FDA Distinguished Scientist Award.
